Ofatumumab, Novartis’s treatment for relapsing forms of multiple sclerosis (MS), is one of numerous new products that are this week up for an opinion by the European Medicines Agency on whether or not they should be granted pan-EU marketing authorization.
EU Approval Verdicts Near For A Bumper Crop Of New Drugs
Novartis, Arvelle, AstraZeneca and Incyte are among a raft of drug sponsors who should find out shortly whether the European Medicines Agency will vote in favor of approving their products for use in the EU.
